Therapies that are easy to administer, regulate underlying type 2 inflammation, and reduce disease progression in eoe are desirable This review focuses on dupilumab, which is the only food and drug administration (fda) approved biologic therapy for eoe. Serious side effects can occur Please see important safety information and prescribing information and patient information on website. It is approved for eoe in children 1 year and older who weigh at least 15 kg (33 lb) with eoe. The significant superiority of biologic therapies over placebo controls and the high safety profile of biologics confirm their value for clinical use and dissemination
This review focuses on biologics therapy in eoe. Dupixent is an injectable biologic medicine Here’s how it helps with eosinophilic esophagitis. It is indicated for adult and pediatric patients aged 1 year and older who weigh at least 33 pounds (15 kg). The recent approval of dupilumab for treatment of eosinophilic esophagitis (eoe), research into better biomarkers, and the anticipated availability of a metric to assess eoe severity all bode well for patients Speakers considered the ramifications of these developments
